Navigation Links
The Melanoma Research Alliance Foundation supports CNIO research
Date:4/23/2013

A consortium led by the Spanish National Cancer Research Centre's researcher Mara S. Soengas −Programme Director of the Centres Molecular Pathology Programme and Leader of the CNIO Melanoma Group− has been selected to receive funding from the Melanoma Research Alliance (MRA), the most important private international melanoma research foundation, in order to advance research in melanoma; this type of skin tumour represents one of oncology's biggest challenges due to its high incidence and malignancy.

The main goals of the project, which has been awarded $900,000, are aimed at generating molecular tools and validating new compounds that block the formation of lymphatic vessels, one of the main routes that cancer cells use to conquer new organs and generate metastasis.

To this end, Soengas will coordinate the work of world-leading researchers in the fields of oncology, pathology, dermatology, medical chemistry or tumour spectrometry, from institutions such as the Swiss Federal Institute of Technology in Munich, the National Institute of Health and Medical Research in Paris, Ludwig Maximilian University in Munich or the Weill Cornell Medical College in New York.

According to Soengas, for decades, the prognosis for patients with melanoma has been largely defined by the presence or absence of tumour cells in the lymph nodes adjacent to the tumour. "Up until now, however, we have not been able to detect the activation of the lymphatic vessels (lymphangiogenesis) before melanoma cells disseminate through the organism", she adds.

This project seeks to provide a solution to this problem, in addition to validating efficient anti-metastatic drugs. "We have generated the first melanoma models to visualise the activation of lymphangiogenesis in vivo. These models will also allow us to carry out pharmacological studies to determine the efficiency and stability of new anti-metastatic therapies", says CNIO researcher.

Further
'/>"/>

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Surgery Rates Rising for Non-Melanoma Skin Cancer: Study
2. Moffitt Cancer Center researchers working at frontiers of melanoma research
3. Women More Likely to Survive Melanoma Than Men: Study
4. Scientists Map Melanomas Genome
5. Two-Drug Combo May Be Safe for Melanoma Treatment
6. Melanoma a Big Threat to Older Men
7. Fish shed light on human melanoma
8. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
9. New Melanoma Drug May Extend Survival
10. New Guidelines Issued for Biopsy Use in Melanoma Patients
11. Melanoma-promoting gene discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Haelle HealthDay Reporter MONDAY, ... experience a severe abusive head trauma before the age of ... new study. In addition, among those who survive ... the study found. Abusive head trauma includes shaken baby ... suffers head injuries, according to background information in the study. ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter ... Daily low-dose aspirin therapy may not have significant heart-health ... The study, which involved more than 14,000 Japanese people ... heart-related deaths or non-fatal heart attacks and strokes between ... "It indicates that primary prevention with daily low-dose ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter , ... stroke patients can safely take aspirin combined with a blood-thinning ... increase a patient,s risk of early death, according to a ... American Heart Association in Chicago. The report was also published ... of data from more than a dozen clinical trials revealed ...
(Date:11/18/2014)... MONDAY, Nov. 17, 2014 (HealthDay News) -- Until recently, insect-transmitted ... America, but it has made its way to the United ... fatal illness is typically transmitted via the bite of the ... night. And now a new study suggests that common bedbugs ... bedbug can acquire and transmit the parasite. Our next step ...
(Date:11/17/2014)... CA (PRWEB) November 17, 2014 A ... thousands of patients throughout the country are turning back ... than ever before. This is because the company has ... to their already impressive collection of prescription and non-prescription ... who have incorporated Diet Doc’s best anti-aging ...
Breaking Medicine News(10 mins):Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 4Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 3Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3Health News:Bedbugs Could Be Potential New Source of Tropical Disease in U.S. 2Health News:Bedbugs Could Be Potential New Source of Tropical Disease in U.S. 3Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 3
... ... commitment to consumer privacy protection , ... Westlake Village, CA and San Francisco, CA (PRWEB) September 1, 2009 ... has been certified to display the TRUSTe Privacy Seal, which demonstrates its commitment to ...
... EDINBURGH, Scotland, September 1 Aircraft Medical,(Aircraft), the UK ... to its R&D, business development and sales teams since January ... staff is in line with the Company,s commitment to,expanding the ... business development and R&D activities. , ...
... The American Academy of Otolaryngology Head and ... only--national clinical practice guideline to help healthcare practitioners ... as dysphonia. The guideline emphasizes evidence-based management of ... prevalence of this common vocal health issue. ...
... , , DENVER, Aug. 31 ... of kidney care services for those diagnosed with chronic kidney disease ... leading health care industry publications, named Kent Thiry, Chairman and CEO ... Healthcare in 2009. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ) ...
... NASHVILLE, Tenn., Aug. 31 Cumberland Pharmaceuticals Inc. (Nasdaq: ... on hospital acute care and gastroenterology markets, today announced that ... Global Life Sciences Conference in New York at 11:00 a.m. ... provide an update on the Company and its Caldolor product, ...
... Pa., Aug. 31 Endo Pharmaceuticals (Nasdaq: ENDP ) announced today ... Thursday, Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, Chief Financial ... , The presentation will be webcast live and can be accessed ... , , About Endo , ...
Cached Medicine News:Health News:The People's Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 2Health News:The People's Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 3Health News:Aircraft Reports Material Expansion and Staff Increase 2Health News:National guideline released for the treatment of hoarseness 2Health News:National guideline released for the treatment of hoarseness 3Health News:DaVita CEO Kent Thiry Honored as One of Modern Healthcare's 100 Most Powerful People in Healthcare 2Health News:Cumberland Pharmaceuticals to Present at UBS Global Life Sciences Conference in New York on September 21, 2009 2Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2
(Date:11/17/2014)... CHICAGO, Ill. , Nov. 17, 2014  AbbVie (NYSE: ... Global Healthcare Conference in London on ... president and chief financial officer, will make a formal presentation ... time.) A live audio webcast of the ... at www.abbvieinvestor.com .  An archived edition of the session ...
(Date:11/17/2014)... , Nov. 17, 2014   Wilson Therapeutics ... start of a Phase 2 clinical study to evaluate ... in Wilson Disease, a rare genetic disorder and designated ... process copper. "We are delighted to proceed ... as a next step in the development program for ...
(Date:11/16/2014)... AUSTIN, Texas , Nov. 16, 2014  Hanger, ... it is postponing the release of its third quarter ... earnings conference call to allow additional time for the ... The Company will release its third quarter financial results ... review of its third quarter financial statements. ...
Breaking Medicine Technology:Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 2Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 3
... Inc. , a company that manufactures and sells a ... in specific markets outside the United States through a ... new BIOSAFE-treated Ultra Sensitive facemasks begin to reduce microorganisms ... and have further proven to be effective against Influenza ...
... , NEW YORK, Oct. 13 Reportlinker.com ... is available in its catalogue. , ... Outlook to 2010: Marketing and Sales Strategies ... , http://www.reportlinker.com/p0154807/Reportlinker-Adds-Global-Drug-Manufacturing-Industry-Outlook-to-2010-Marketing-and-Sales-Strategies-and-the-Impact-of-Recession-and-Recovery.html ...
Cached Medicine Technology:BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 2BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 3BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 4Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 2Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 3Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 4Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 5Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 6Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 7Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 8Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 9Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 10Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 11Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 12Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 13Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 14Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 15Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 16Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 17Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 18Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 19Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 20
... end transcription services. Zodiac offers two ... either submitted over the phone via ... 24 hours a day, 7 days ... recorded on a digital handheld recorder ...
... Achieve high-speed productivity in the lab ... system, dedicated for pre- and post-analytical sorting ... HSS selectively decaps and then sorts primary ... to save time, labor, and eliminate ...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Similar to Model 530, but just 37 inches long and with only one drape....
Medicine Products: